risankizumab + ABBV-382 + lutikizumab

This is an **experimental combination therapy** consisting of risankizumab, ABBV-382, and lutikizumab, being investigated for the treatment of moderate to severe Crohn’s disease. Each component targets immune pathways involved in inflammation: - **Risankizumab** is a humanized monoclonal antibody targeting interleukin-23 (IL-23), inhibiting its role in the inflammatory cascade. - **ABBV-382** is a monoclonal antibody that targets integrin α4β7, inhibiting lymphocyte trafficking to the gut. - **Lutikizumab** is a monoclonal antibody that neutralizes interleukin-1α (IL-1α) and interleukin-1β (IL-1β), reducing inflammation. The combination is under investigation in Phase 2 clinical trials as part of a platform study to assess the efficacy and safety as both monotherapies and in various combinations. Routes of administration are intravenous or subcutaneous for risankizumab and ABBV-382, and subcutaneous for lutikizumab. The developer and lead trial sponsor is AbbVie[1][4][6][9].